LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Stoumpos, Sokratis; Jardine, Alan G.; Mark, Patrick B. (2015)
Publisher: John Wiley & Sons Ltd
Languages: English
Types: Article
Subjects: RC, RD

Classified by OpenAIRE into

mesheuropmc: surgical procedures, operative
Identifiers:doi:10.1111/tri.12413
Kidney transplantation is the optimal treatment for patients with end stage renal disease (ESRD) who would otherwise require dialysis. Patients with ESRD are at dramatically increased cardiovascular (CV) risk compared to the general population. As well as improving quality of life, successful transplantation accords major benefits by reducing cardiovascular risk in these patients. Worldwide, cardiovascular disease remains the leading cause of death with a functioning graft and therefore is a leading cause of graft failure. This review focuses on the mechanisms underpinning excess cardiovascular morbidity and mortality and current evidence for improving cardiovascular risk in kidney transplant recipients. Conventional cardiovascular risk factors such as hypertension, diabetes mellitus, dyslipidaemia, and pre-existing ischaemic heart disease are all highly prevalent in this group. In addition, kidney transplant recipients exhibit a number of risk factors associated with pre-existing renal disease. Furthermore, complications specific to transplantation may ensue includingreduced graft function, side effects of immunosuppression and post transplantation diabetes mellitus. Strategies to improve cardiovascular\ud outcomes post transplantation may include pharmacological intervention including lipid lowering or antihypertensive therapy, optimisation of graft function, lifestyle intervention and personalising immunosuppression to the\ud individual patients risk profile.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • JAMA. 1993; 270: 1339-43.
    • recipients of a first cadaveric transplant. N Engl J Med. 1999; 341: 1725-
    • Ontario, Canada. J Am Soc Nephrol. 2000; 11: 917-22.
    • Nephrol. 2005; 16: 1859-65.
    • elevated body mass index. Kidney Int. 2003; 63: 647-53.
    • wait-listed transplant candidates. J Am Soc Nephrol. 2001; 12: 589-97.
    • the survival benefit of kidney transplantation. JAMA. 2005; 294: 2726-33.
    • death provide survival benefit. J Am Soc Nephrol. 2010; 21: 1015-21.
    • Transplantation. 1998; 66: 1651-9.
    • kidney retransplantation. Transplantation. 2006; 82: 669-74.
    • heart disease risk after renal transplantation. J Am Soc Nephrol. 2000; 11:
    • renal transplant recipients. Transplantation. 2000; 70: SS41-5.
    • cardiovascular disease in chronic renal disease: what do we know? What 93. Paoletti E, Marsano L, Bellino D, Cassottana P, Cannella G. Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: a 1 year, randomized, controlled trial. Transplantation. 2012; 93: 503-8.
    • e94. Kurtz A, Della Bruna R, Kühn K. Cyclosporine A enhances renin secretion and production in isolated juxtaglomerular cells. Kidney Int. 1988; 33:
    • l 947-53. 95. Mason J, Müller-Schweinitzer E, Dupont M, et al. Cyclosporine and the
    • c renin-angiotensin system. Kidney Int Suppl. 1991; 32: S28-32. 96. Mourer JS, de Koning EJ, van Zwet EW, Mallat MJ, Rabelink TJ, de Fijter JW.
    • t recipients. Transplantation. 2013; 96: 49-57. 97. Mulay AV, Hussain N, Fergusson D, Knoll GA. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a
    • r systematic review of randomized trials. Am J Transplant. 2005; 5: 1748- 56. 98. Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after
    • A transplantation. Am J Transplant. 2009; 9: 1876-85. 99. Egbuna OI, Davis RB, Chudinski R, et al. Outcomes with conversion from calcineurin inhibitors to sirolimus after renal transplantation in the context of steroid withdrawal or steroid continuation. Transplantation. 2009; 88: 684-92. 100. Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of
    • d early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant. 2009; 9: 1115-23. 101. Cosio FG, Falkenhain ME, Pesavento TE, et al. Patient survival after renal transplantation: II. The impact of smoking. Clin Transplant. 1999; 13: 336-
    • e 41. 102. Kasiske BL, Klinger D. Cigarette smoking in renal transplant recipients. J
    • t Am Soc Nephrol. 2000; 11: 753-9. 103. Group KDIGOKTW. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009; 9 Suppl 3: S1-155. 104. Baker R, Jardine A, Andrews P. Renal Association Clinical Practice
    • p Guideline on post-operative care of the kidney transplant recipient. Nephron Clin Pract. 2011; 118 Suppl 1: c311-47. 105. de Vries AP, Bakker SJ, van Son WJ, et al. Metabolic syndrome is
    • e associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant. 2004; 4: 1675-83. 106. Meier-Kriesche HU, Arndorfer JA, Kaplan B. The impact of body mass
    • c index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation. 2002; 73: 70-4. 107. Abbott KC, Reynolds JC, Taylor AJ, Agodoa LY. Hospitalized atrial fibrillation after renal transplantation in the United States. Am J
    • c Transplant. 2003; 3: 471-6. 108. Zelle DM, Corpeleijn E, Stolk RP, et al. Low physical activity and risk of cardiovascular and all-cause mortality in renal transplant recipients. Clin J Am Soc Nephrol. 2011; 6: 898-905. 109. Didsbury M, McGee RG, Tong A, et al. Exercise training in solid organ transplant recipients: a systematic review and meta-analysis. Transplantation. 2013; 95: 679-87. 110. Ducloux D, Motte G, Challier B, Gibey R, Chalopin JM. Serum total
    • e homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol. 2000;
    • l 11: 134-7. 111. Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering and
    • i Transplantation trial. Circulation. 2011; 123: 1763-70. 112. Rigatto C, Parfrey P, Foley R, Negrijn C, Tribula C, Jeffery J. Congestive
    • t heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol. 2002; 13: 1084-90.
    • r113. Abedini S, Holme I, März W, et al. Inflammation in renal transplantation. Clin J Am Soc Nephrol. 2009; 4: 1246-54. 114. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation. 2003; 75: 1291-5.
    • A 115. Haidinger M, Werzowa J, Hecking M, et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation--a randomized, double-blind, placebo-controlled trial. Am J Transplant. 2014; 14: 115-23. 116. Hecking M, Haidinger M, Döller D, et al. Early basal insulin therapy
    • d decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol. 2012; 23: 739-49. 117. Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, doubleblind, placebo-controlled multicenter trial comparing early (7 day)
    • e corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008; 248: 564-77.
    • t118. Vincenti F, Schena FP, Paraskevas S, et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant. 2008; 8: 307-16. 119. Rizzari MD, Suszynski TM, Gillingham KJ, et al. Ten-year outcome after
    • p rapid discontinuation of prednisone in adult primary kidney transplantation. Clin J Am Soc Nephrol. 2012; 7: 494-503. 120. Vanrenterghem Y, Lebranchu Y, Hené R, Oppenheimer F, Ekberg H.
    • e Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation. 2000; 70: 1352-9.
    • c121. Ahsan N, Hricik D, Matas A, et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil--a prospective randomized study. Steroid Withdrawal Study Group. Transplantation. 1999; 68: 1865-74.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article